市场调查报告书
商品编码
1413853
製药业人工智慧市场:按产品、技术、应用和最终用户划分 - 2024-2030 年全球预测Artificial Intelligence in Pharmaceutical Market by Offering (Hardware, Services, Software), Technology (Computer Vision, Context-Aware Computing, Machine Learning), Applications, End-users - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
人工智慧在製药领域的市场规模预计2023年为162.1亿美元,2024年达到207.6亿美元,预计2030年将达到973.5亿美元,复合年增长率为29.18%。
人工智慧在製药领域的全球市场
主要市场统计 | |
---|---|
基准年[2023] | 162.1亿美元 |
预测年份 [2024] | 207.6亿美元 |
预测年份 [2030] | 973.5亿美元 |
复合年增长率(%) | 29.18% |
製药市场中的人工智慧(AI)是指将先进的机器学习演算法、自然语言处理和资料分析技术整合到全球製药业的药物研发、开发和製造流程中。为了改善治疗效果而对个人化医疗的需求不断增长,以及基因组学和高通量技术的进步产生了大量复杂的资料,需要先进的分析技术。然而,用于训练机器学习模型的精选资料集的可得性有限,阻碍了人工智慧在医学中的采用。然而,将巨量资料分析与人工智慧结合还可以提高我们对各种疾病分子机制的理解,并识别可能成为未来药物标靶的新型生物标记。
区域洞察
在美国,由于先进技术的早期采用和政府的支援政策,医药人工智慧市场的环境正在改善。美国拥有多家领先的人工智慧新兴企业,它们利用人工智慧进行药物研发、分子建模、临床试验优化和个人化医疗。在美国,大型製药企业正在与人工智慧主导的新兴企业合作,并大力投资研究,以加速药物研发发现和开发。在欧洲地区,法国、德国、英国等国纷纷推出国家战略,推动人工智慧在医药等各产业的应用。儘管与其他地区相比进展缓慢,但中东国家正在透过人工智慧投资取得进展。非洲的潜力在于透过其不断发展的製药生态系统来应对其独特的医疗保健挑战。在亚太地区,以中国、日本和印度为首的人工智慧药物领域正在取得显着进展。此外,公共和私人对製药基础设施的投资不断增加,为引入人工智慧创造了积极的环境。
FPNV定位矩阵
FPNV 定位矩阵对于评估製药市场中的人工智慧至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对製药市场人工智慧供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵考察,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1-市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2-市场开拓:我们深入研究利润丰厚的新兴市场,并分析它们在成熟细分市场中的渗透率。
3- 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4-竞争力评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5- 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1-人工智慧在医药领域的市场规模与预测是多少?
2-在人工智慧製药市场的预测期内,有哪些产品、细分市场、应用和领域需要考虑投资?
3-人工智慧在製药市场的技术趋势和法律规范是什么?
4-製药市场人工智慧主要供应商的市场占有率是多少?
5-进入医药人工智慧市场的合适型态和策略手段是什么?
[199 Pages Report] The Artificial Intelligence in Pharmaceutical Market size was estimated at USD 16.21 billion in 2023 and expected to reach USD 20.76 billion in 2024, at a CAGR 29.18% to reach USD 97.35 billion by 2030.
Global Artificial Intelligence in Pharmaceutical Market
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 16.21 billion |
Estimated Year [2024] | USD 20.76 billion |
Forecast Year [2030] | USD 97.35 billion |
CAGR (%) | 29.18% |
Artificial intelligence (AI) in the pharmaceutical market refers to integrating advanced machine learning algorithms, natural language processing, and data analytics technologies into the drug discovery, development, and manufacturing processes of the global pharmaceutical industry. The growing demand for personalized medicine to improve treatment outcomes and advancements in genomics and high-throughput technologies generate large volumes of complex data requiring advanced analytical techniques. However, the limited availability of curated datasets for training machine learning models hinders the adoption of AI in pharmaceuticals. Nevertheless, integrating big data analytics with AI may also facilitate a better understanding of molecular mechanisms underlying various diseases or identify novel biomarkers that could be targets of future drugs; this further creates lucrative opportunities for the market.
Regional Insights
America provides an improved landscape for the AI in pharmaceutical market with an early adoption of advanced technologies and supportive government policies. The United States is home to several leading AI startups leveraging AI for drug discovery, molecular modeling, clinical trials optimization, and personalized medicine. In the U.S., major pharmaceutical firms are partnering with AI-driven startups and investing heavily in research to expedite drug discovery and development. In the European region, countries such as France, Germany, and the United Kingdom have introduced national strategies propelling AI applications across industries, including pharmaceuticals. Although slower in comparison to other regions, Middle Eastern countries are advancing through investment in AI. Africa's potential lies in addressing unique healthcare challenges through its developing pharma ecosystem. The Asia Pacific region showcases significant growth in AI-driven pharmaceutical advancements with China, Japan, and India at the forefront. In addition, increasing public-private investments in pharmaceutical manufacturing infrastructure provides a positive landscape for AI deployments.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Artificial Intelligence in Pharmaceutical Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Artificial Intelligence in Pharmaceutical Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Artificial Intelligence in Pharmaceutical Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aspen Technology Inc, Atomwise Inc, BenevolentAI SA, BioSymetrics Inc., BPGbio Inc., Butterfly Network, Inc., Cloud Pharmaceuticals, Inc., CloudMedX Inc., Cyclica Inc, Deargen Inc, Deep Genomics Incorporated, Euretos Services BV, Exscientia plc, Google LLC, Insilico Medicine, Intel Corporation, International Business Machines Corporation, InveniAI LLC, Isomorphic Labs, Microsoft Corporation, Novo Nordisk A/S, Oracle Corporation, Sanofi SA, Turbine Ltd., Viseven Europe OU, and XtalPi Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Artificial Intelligence in Pharmaceutical Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Artificial Intelligence in Pharmaceutical Market?
3. What are the technology trends and regulatory frameworks in the Artificial Intelligence in Pharmaceutical Market?
4. What is the market share of the leading vendors in the Artificial Intelligence in Pharmaceutical Market?
5. Which modes and strategic moves are suitable for entering the Artificial Intelligence in Pharmaceutical Market?